List of Excipients in API nadofaragene firadenovec-vncg
✉ Email this page to a colleague
Detailed excipient profiles for nadofaragene firadenovec-vncg
Excipient focus: (N-(3-CHOLAMIDOPROPYL)-N-(3-LACTOBIONAMIDOPROPYL))CHOLAMIDE
nadofaragene firadenovec-vncg drug variants containing (N-(3-CHOLAMIDOPROPYL)-N-(3-LACTOBIONAMIDOPROPYL))CHOLAMIDE
| Company | Ingredient | NDC |
|---|---|---|
| Ferring Pharmaceuticals | nadofaragene firadenovec-vncg | 55566-1050 |
| >Company | >Ingredient | >NDC |
nadofaragene firadenovec-vncg drug variants not containing (N-(3-CHOLAMIDOPROPYL)-N-(3-LACTOBIONAMIDOPROPYL))CHOLAMIDE
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: CITRIC ACID MONOHYDRATE
nadofaragene firadenovec-vncg drug variants containing CITRIC ACID MONOHYDRATE
| Company | Ingredient | NDC |
|---|---|---|
| Ferring Pharmaceuticals | nadofaragene firadenovec-vncg | 55566-1050 |
| >Company | >Ingredient | >NDC |
nadofaragene firadenovec-vncg drug variants not containing CITRIC ACID MONOHYDRATE
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: GLYCERIN
nadofaragene firadenovec-vncg drug variants containing GLYCERIN
| Company | Ingredient | NDC |
|---|---|---|
| Ferring Pharmaceuticals | nadofaragene firadenovec-vncg | 55566-1050 |
| >Company | >Ingredient | >NDC |
nadofaragene firadenovec-vncg drug variants not containing GLYCERIN
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: HYDROXYPROPYL BETADEX
nadofaragene firadenovec-vncg drug variants containing HYDROXYPROPYL BETADEX
| Company | Ingredient | NDC |
|---|---|---|
| Ferring Pharmaceuticals | nadofaragene firadenovec-vncg | 55566-1050 |
| >Company | >Ingredient | >NDC |
nadofaragene firadenovec-vncg drug variants not containing HYDROXYPROPYL BETADEX
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: MAGNESIUM CHLORIDE
nadofaragene firadenovec-vncg drug variants containing MAGNESIUM CHLORIDE
| Company | Ingredient | NDC |
|---|---|---|
| Ferring Pharmaceuticals | nadofaragene firadenovec-vncg | 55566-1050 |
| >Company | >Ingredient | >NDC |
nadofaragene firadenovec-vncg drug variants not containing MAGNESIUM CHLORIDE
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: POLYSORBATE 80
nadofaragene firadenovec-vncg drug variants containing POLYSORBATE 80
| Company | Ingredient | NDC |
|---|---|---|
| Ferring Pharmaceuticals | nadofaragene firadenovec-vncg | 55566-1050 |
| >Company | >Ingredient | >NDC |
nadofaragene firadenovec-vncg drug variants not containing POLYSORBATE 80
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: SODIUM PHOSPHATE, MONOBASIC, DIHYDRATE
nadofaragene firadenovec-vncg drug variants containing SODIUM PHOSPHATE, MONOBASIC, DIHYDRATE
| Company | Ingredient | NDC |
|---|---|---|
| Ferring Pharmaceuticals | nadofaragene firadenovec-vncg | 55566-1050 |
| >Company | >Ingredient | >NDC |
nadofaragene firadenovec-vncg drug variants not containing SODIUM PHOSPHATE, MONOBASIC, DIHYDRATE
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: SUCROSE
nadofaragene firadenovec-vncg drug variants containing SUCROSE
| Company | Ingredient | NDC |
|---|---|---|
| Ferring Pharmaceuticals | nadofaragene firadenovec-vncg | 55566-1050 |
| >Company | >Ingredient | >NDC |
nadofaragene firadenovec-vncg drug variants not containing SUCROSE
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: TRISODIUM CITRATE DIHYDRATE
nadofaragene firadenovec-vncg drug variants containing TRISODIUM CITRATE DIHYDRATE
| Company | Ingredient | NDC |
|---|---|---|
| Ferring Pharmaceuticals | nadofaragene firadenovec-vncg | 55566-1050 |
| >Company | >Ingredient | >NDC |
nadofaragene firadenovec-vncg drug variants not containing TRISODIUM CITRATE DIHYDRATE
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: TROMETHAMINE
nadofaragene firadenovec-vncg drug variants containing TROMETHAMINE
| Company | Ingredient | NDC |
|---|---|---|
| Ferring Pharmaceuticals | nadofaragene firadenovec-vncg | 55566-1050 |
| >Company | >Ingredient | >NDC |
nadofaragene firadenovec-vncg drug variants not containing TROMETHAMINE
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: WATER
nadofaragene firadenovec-vncg drug variants containing WATER
| Company | Ingredient | NDC |
|---|---|---|
| Ferring Pharmaceuticals | nadofaragene firadenovec-vncg | 55566-1050 |
| >Company | >Ingredient | >NDC |
nadofaragene firadenovec-vncg drug variants not containing WATER
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Generic Entry Opportunies 2025 - 2026
NCE-1 Patent Challenge Dates 2025 - 2026
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2025, www.DrugPatentWatch.com.
See Primary Research Papers Citing DrugPatentWatch